ProCE Banner Activity

Testing and Targeting BRCA1/2 in HER2- EBC

Slideset

Get up to date on current and emerging perioperative treatment options for patients with HER2- early breast cancer harboring BRCA mutations.

Released: June 02, 2023

Share

Faculty

Mark E. Robson

Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC